Abstracts tagged "Work Disability"

Abstract Number: 2730 • 2016 ACR/ARHP Annual Meeting
Impact of Disease Flare Perception on Work Productivity and Treatment Satisfaction in Patients with Psoriatic Arthritis in Real World Setting
William Tillett^1,2, James Piercy³, Su Chen⁴ and Fabiana Ganz⁵, ¹Pharmacy and Pharmacology, University of Bath, Bath, United Kingdom, ²Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ³Adelphi Real World, Cheshire, United Kingdom, ⁴AbbVie, North Chicago, IL, ⁵Neuhofstrasse 23, AbbVie, Baar, Switzerland
Background/Purpose: Patients (pts) with psoriatic arthritis (PsA) may experience temporary worsening of symptoms or disease flare, which can be painful enough to interfere with day-to-day…
Abstract Number: 3252 • 2016 ACR/ARHP Annual Meeting
Content Analysis of Ergonomic Recommendations Using the Ergonomic Assessment Tool for Arthritis
Lisa Allyn¹, Lisa Zoller¹, Catherine L. Backman^2,3 and Diane Lacaille^4,5, ¹The University of British Columbia, Vancouver, BC, Canada, ²Department of Occupational Science & Occupational Therapy, The University of British Columbia, Vancouver, BC, Canada, ³Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ⁴Medicine, University of British Columbia, Vancouver, BC, Canada, ⁵Arthritis Research Canada, Richmond, BC, Canada
Background/Purpose: Work cessation and at-work productivity loss are common and early outcomes of inflammatory arthritis (IA). Ergonomic accommodations contribute to successful management of arthritis symptoms…
Abstract Number: 18 • 2016 ACR/ARHP Annual Meeting
The Impact of Disease-Related and Contextual Factors on Work Outcomes in Chronic Inflammatory Arthritis Patients Treated with Biologics: A Systematic Review
Jenny Shu¹, Panos Lambiris² and Claire Bombardier³, ¹Department of Rheumatology, University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, ON, Canada
Background/Purpose: Biological therapy has been shown to have a positive effect on work outcomes, such as work participation and/or work disability in patients with chronic…
Abstract Number: 228 • 2016 ACR/ARHP Annual Meeting
Sick Leave and Disability Pension in Working-Age Gout Patients before and after Diagnosis – a Population Based Case-Control Study
Valgerdur R Sigurdardottir¹, Lennart TH Jacobsson², Panagiota Drivelegka², Anna Svärd^1,3 and Mats Dehlin², ¹Rheumatology Clinic, Falun Hospital, SE-791 82 Falun, Sweden, Falun, Sweden, ²Department of Rheumatology and Inflammation Research, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ³Center for Clinical Research Dalarna, Falun, Sweden
Background/Purpose: Gout is the most common form of inflammatory arthritis with a prevalence of 1.5% in our area in the age group 50-59 years. Gout…
Abstract Number: 549 • 2016 ACR/ARHP Annual Meeting
Work Status in Patients with Rheumatoid Arthritis Who Have Poor Prognostic Factors: Findings from a US Observational Cohort
E Alemao¹, LR Harrold², HJ Litman³, SE Connolly⁴, S Kelly¹, W Hua³, L Rosenblatt¹, S Rebello⁵ and JM Kremer⁶, ¹Bristol-Myers Squibb, Princeton, NJ, ²University of Massachusetts Medical School, Worcester, MA, ³Corrona, Southborough, MA, ⁴Department of Immunology and Inflammation, Bristol-Myers Squibb, Princeton, NJ, ⁵Epidemiology, Corrona, Southborough, MA, ⁶The Albany Medical College, Albany, NY
Background/Purpose: A number of studies have demonstrated the association between disease activity and work productivity in patients (pts) with RA. However, the relationship between work…
Abstract Number: 653 • 2015 ACR/ARHP Annual Meeting
Clinical Responses and Improvements in Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol
Désirée van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Klinikum Bielefeld, Bielefeld, Germany, ⁴UCB Pharma, Brussels, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose: Axial spondyloarthritis (axSpA) includes ankylosing spondylitis (AS) and non-radiographic axSpA (nr-axSpA).1 AS significantly affects patient (pt) workplace productivity in both performance and disease-related absenteeism.2…
Abstract Number: 2481 • 2015 ACR/ARHP Annual Meeting
Work Disability in a Cohort of Patients with Psoriatic Arthritis
Cecilia Zaffarana¹, Osvaldo Luis Cerda¹, Josefina Gallino Yanzi¹, Margarita Landi¹, Emilce Schneeberger¹, Ignacio Carrillo¹, María del Carmen Gonzalez Guzmán¹, Jose A Maldonado Cocco¹, Susana Gagliardi¹ and Gustavo Citera², ¹Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, ²Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina
Background/Purpose: Several studies showed that unemployment and work disability are high in patients with Psoriatic Arthritis (PsA). Te purpose of this study is to evaluate work…
Abstract Number: 2648 • 2015 ACR/ARHP Annual Meeting
Vitality, Presenteeism, and Their Determinants in Patients with Early Rheumatoid Arthritis Treated with a 6-Month Induction Infliximab Therapy Added on a Triple Combination Therapy
Vappu Rantalaiho¹, Marjatta Leirisalo-Repo², Hannu Kautiainen³, Petri Mankinen⁴, Janne Martikainen⁵ and Kari Puolakka⁶, ¹Department of Internal Medicine, Center for Rheumatic Diseases, Tampere University Hospital, Tampere, Finland, ²Rheumatology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ³Unit of Primary Health Care, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, ⁴Pharmacoeconomics & Outcomes Research Unit (PHORU), School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁵Pharmacoeconomics and Outcomes Research Unit, School of Pharmacy, University of Eastern Finland, Kuopio, Finland, ⁶Department of Medicine, South Karelia Central Hospital, Lappeenranta, Finland
Background/Purpose: To evaluate vitality, reduced paid and unpaid work ability, and productivity losses for patients with early rheumatoid arthritis (RA) available for work force at…
Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 2560 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
Desiree van der Heijde¹, Juergen Braun², Martin Rudwaleit³, Oana Purcaru⁴ and Arthur Kavanaugh⁵, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumazentrum Ruhrgebiet, Herne, Germany, ³Endokrinologikum, Berlin, Germany, ⁴Allee De La Recherche 60, UCB Pharma, Anderlecht, Belgium, ⁵University of California San Diego, La Jolla, CA
Background/Purpose Axial spondyloarthritis (axSpA) includes both ankylosing spondylitis (AS, meeting modified New York criteria) and axSpA with no sacroiliitis on X-ray (non-radiographic axSpA, nr-axSpA). Previous…
Abstract Number: 2487 • 2014 ACR/ARHP Annual Meeting
Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis
V. Strand¹, R. Riese², R. Gerber², D. Gruben², A.G. Bushmakin², E.Y. Mahgoub³ and G. Wallenstein², ¹Biopharmaceutical Consultant, Portola Valley, CA, ²Pfizer Inc, Groton, CT, ³Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Here we describe health care resource utilization (HCRU) and work…
Abstract Number: 2034 • 2014 ACR/ARHP Annual Meeting
A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA)
Mihir D. Wechalekar¹, Steve Quinn², Susan Lester³, Ella Shanahan⁴, Robert Metcalf⁵, E. Michael Shanahan⁶ and Susanna Proudman^4,7, ¹Flinders University School of Medicine, Adelaide, Australia, ²Flinders Clinical Effectiveness, Flinders University, Adelaide, Australia, ³Rheumatology Unit, Queen Elizabeth Hospital, Woodville South, Australia, ⁴University of Adelaide, Discipline of Medicine, Adelaide, Australia, ⁵University of Adelaide, Adelaide, Australia, ⁶Rheumatology, Flinders University, Bedford Park, South Australia, Australia, ⁷Department of Rheumatology, Royal Adelaide Hospital, SA, Australia
Background/Purpose Historical data (1)indicate a third of patients with RA are unable to work within the first 5 years of diagnosis. Our aim was to…
Abstract Number: 1552 • 2014 ACR/ARHP Annual Meeting
Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis
Arthur Kavanaugh¹, Dafna D. Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Swedish Medical Center and University of Washington, Seattle, WA
Background/Purpose Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 The previous results…
Abstract Number: 577 • 2014 ACR/ARHP Annual Meeting
A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, M Turina⁴, M. van Oosterhout⁵, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands
Background/Purpose: Ankylosing spondylitis is associated with work productivity (WP) loss and a decreased health-related quality of life (HRQoL). Little is known about WP loss and…
Abstract Number: 575 • 2014 ACR/ARHP Annual Meeting
Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort
A Roeterink¹, M de Hooge², R. van den Berg², H Dagfinrud³, R Landewé⁴, M. van Oosterhout⁵, R Ramonda⁶, D. van der Heijde¹ and F van Gaalen², ¹Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Oslo City Dept of Rheumat, Diakonhjemmet Hospital, Oslo, Norway, ⁴Division of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Groene Hartziekenhuis, Gouda, Netherlands, ⁶Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: In early onset axial spondyloarthritis (axSpA), not much is known about the relationship between disease activity and work productivity loss (WPL) or disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].